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Purpose: The use of implantable cardioverter defibrillators (ICDs) to prevent sudden cardiac death is 
increasing in children and adolescents. This study investigated the use of ICDs in children with congenital 
heart disease.
Methods: This retrospective study was conducted on the clinical characteristics and effectiveness of 
ICD implantation at the department of pediatrics of a single tertiary center between 2007 and 2011.
Results: Fifteen patients underwent ICD implantation. Their mean age at the time of implantation was 
14.5±5.4 years (range, 2 to 22 years). The follow-up duration was 28.9±20.4 months. The cause 
of ICD implantation was cardiac arrest in 7, sustained ventricular tachycardia in 6, and syncope in 2 
patients. The underlying disorders were as follows: ionic channelopathy in 6 patients (long QT type 3 
in 4, catecholaminergic polymorphic ventricular tachycardia [CPVT] in 1, and J wave syndrome in 1), 
cardiomyopathy in 5 patients, and postoperative congenital heart disease in 4 patients. ICD coils were 
implanted in the pericardial space in 2 children (ages 2 and 6 years). Five patients received appropriate 
ICD shock therapy, and 2 patients received inappropriate shocks due to supraventricular tachycardia. 
During follow-up, 2 patients required lead dysfunction-related revision. One patient with CPVT suffered 
from an ICD storm that was resolved using sympathetic denervation surgery. 
Conclusion: The overall ICD outcome was acceptable in most pediatric patients. Early diagnosis and 
timely ICD implantation are recommended for preventing sudden death in high-risk children and patients 
with congenital heart disease. 
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Introduction
The annual incidence of sudden cardiac death in children is low, 1/100,000 individuals 
according to population based studies
1). Arrhythmic causes are associated with electrical 
diseases such as ventricular tachycardia, ionic channelopathy
2). Postoperative arrhythmia 
after repair of congenital heart disease is also one of the causes of sudden cardiac death 
in children
3). To prevent sudden cardiac death, implantable cardioverter defibrillator (ICD) 
therapy has become an established standard care in adults. After the first ICD therapy in a 
young patient in 1989
4), it has been used with increasing frequency in children and in patients 
with congenital heart disease
5). However pediatric ICD therapy has many limitations and 
only 1% of all ICD implantations are for pediatric patients
6-8). Furthermore the experience 
of pediatric ICD implantation is very limited and there is only one published case report 
on pediatric ICD in Korea
9). The purpose of this study was to document the clinical http://dx.doi.org/10.3345/kjp.2013.56.3.125
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conditions requiring ICD implantation and effectiveness and 
limitations of ICD in children and congenital heart disease. 
Materials and methods
We retrospectively reviewed the records of pediatric patients who 
underwent ICD implantation at Seoul National University Children’s 
Hospital between 2007 and 2011. A total fifteen patients underwent 
ICD implantation during this period. Patient characteristics, 
indication of ICD implantation, implan  tation procedure, the 
effectiveness and complications were analyzed. Implant electrical 
parameter, type of lead and generator, defibril  lation threshold, and 
initial R wave were also examined. 
Two methods for ICD implantation were used, which were 
through the transvenous and epicardial routes. In the small 
children for the epicardial ICD implantation, we operated through 
the sternotomy and implanted a generator in the abdominal area. 
The indication for the primary prevention of sudden death was 
the ICD implantation for cases that were at risk for but did not 
yet have an episode of sustained ventricular tachycardia (VT), 
ventricular fibrillation (VF), or resuscitated cardiac arrest. Secondary 
prevention of sudden death was for cases that had survived a 
prior sudden cardiac arrest or sustained VT. 
All parameters were expressed as the mean±standard deviation. 
Results
1. Patient’s characteristics
A total of 15 patients underwent ICD implantations. There 
were six females and nine males. The mean age at implantation 
was 14.5±5.4 years (range, 2 to 22 years). Additionally, the mean 
weight at implantation was 46.7±16.2 kg (range, 9.9 to 70 kg). 
The mean follow-up duration was 28.9±20.4 months (range, 4 to 59 
months).
The underlying disorders were as follows: ionic channelopathy 
in 6 patients (long QT syndrome [LQTS] in 4 patients, catechola-
minergic polymorphic ventricular tachycardia [CPVT] in 1 pa-
tient, and J wave syndrome in 1 patient); cardiomyopathy in 5 
patient (hypertrophic cardiomyopathy in 2 patients, glycogen 
storage disease related cardiomyopathy in 1 patient, uremic 
cardiomyopathy in 1 patient, unspecified cardiomyopathy in 
1 patient), and congenital heart disease in 4 patients (tetralogy of 
Fallot in 2 patients, double outlet right ventricle in 1 patient, 
pulmonary atresia with ventricular septal defect in 1 patient). 
Among the 4 LQTS patients, 3 patients were diagnosed by genetic 
testing, showing a type 3 LQTS with a SCN5A mutation. The 
most common underlying diagnosis was primarily electrical 
disease of ionic channelopathy. 
2. Indication of ICD 
The indication for ICD was cardiac arrest in 7 patients, sustained 
VT in 6 patients, and syncope in 2 patients (Table 1). Among the 
15 patients, ICD was implanted as secondary prevention in 
13 patients and as primary prevention in 2 patients. A patient 
Table 1. Patient characteristics 
Sex Age at ICD (yr) ICD duration (mo) Diseases Indication Route Initial DFT (J) Appropriate  shock 
F 10 12 LQTS 3 OHCA, VF Transvenous 20   0
M 20 38 TOF VT Transvenous 20   0
M 16 59 DORV  VT Transvenous 10   1
F   6 27 LQTS 3 OHCA,VF Epicardial  10   2
M 17 53 CPVT VT Transvenous 15 10
M 21 49  PA VT Transvenous 15   0
M   2 32 LQTS 3 OHCA Epicardial  20   4
F 14 58 CMP VT Transvenous 15   0
M 22 14 Uremic CMP OHCA,VT Transvenous 15   0
M 12 12 TOF  VT Transvenous 10   0
F 16 48 HCM OHCA,VT Transvenous 15   3
F 15 15 CMP  OHCA Transvenous 10   0
M 18   9 J wave S   Syncope Transvenous 15   0
M 14   4 LQTS OHCA,VF Transvenous 10   0
F 14   4 HCM Syncope Transvenous 20   0
ICD, implantable cardioverter defibrillator; DFT, defibrillation threshold; LQTS 3, type 3 long QT syndrome; OHCA, out hospital cardiac arrest; VF, ventricular 
fibrillation; TOF, tetralogy of Fallot; VT, ventricular tachycardia; DORV, double outlet of right ventricle; CPVT, catecholaminergic polymorphic ventricular tachycardia; 
PA, pulmonary atresia; CMP, cardiomyopathy; HCM, hypertrophic cardiomyopathy; J wave S, J wave syndrome; LQTS, long QT syndrome.127 http://dx.doi.org/10.3345/kjp.2013.56.3.125
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with J wave syndrome, who received the ICD implantation as 
a primary prevention, had a strong family history of sudden 
cardiac death in young adults and he also had a history of syn-
cope. During the electrophysiologic study, polymorphic VT was 
induced. The other patient with an ICD for primary preven  tion had 
hypertrophic cardiomyopathy with syncope and very severe 
septal hypertrophy. 
Besides ventricular arrhythmias, associated arrhythmias were 
observed in 3 patients, sinus bradycardia in 2 patients, and atrial 
tachycardia in 2 patients.
3. Implantation procedures and types of ICD 
The transvenous approach and the subpectoral positioning of 
active can were used in patients with a body weight more than 
30 kg. In the younger children and those with less than 30 kg of 
body weight, the ICD was implanted via the epicardial route (Fig. 
1). 
Among the 15 patients, 13 received the ICD through the trans-
venous route. The average age of the transvenous ICD group 
was 16.1 years old (range, 10 to 22 years) and their average 
weight was 52.7 kg (range, 30 to 70 kg). Instead of transvenous 
ICD, epicardial ICD implantation was used only for 2 patients. 
Their ages and weights were 2 and 6 years, and 9.9 and 26 kg 
respectively. For the epicardial ICD implantation, a single shock 
coil was placed at the pericardial transverse sinus using the 
transvenous ICD lead system after median sternotomy. A 
subrectus pocket was made in the upper abdominal wall to ac-
commodate the ICD device (Fig. 1B). 
Most patients had single chamber leads; however, 3 patients 
required double chamber leads with both atrial and ventricular 
leads due to associated sinus bradycardia in 2 LQTS patients 
and atrial tachycardia in a CPVT patient. Additionally, 7 patients 
received a double shock coil with a superior vena cava coil for 
down-regulating the defibrillation threshold. The mean initial 
defibrillation threshold (DFT) was 14.6±3.9 J (range, 10 to 20 J). 
The initial R wave was 9.8±3.9 mV and the latest checked R wave 
was 8.8±4.1 mV. In the case of the epicardial lead, the mean DFT 
was 10 and 20 J, and the R wave was 8.7 and 15.8 mV.
4. Effectiveness of ICD and follow-up  
Five patients received the appropriate shock therapy for VT/
VF for a total of 20 times (Table 1). In addition, the time interval 
between the ICD implantation to the first appropriate shock 
was 10.8±7.6 months (range, 3 to 24 months). Two patients 
with primary prevention have not received shock therapy for 
12 months and 15 months of follow-up. On the other hand, a 
repaired tetralogy of Fallot patient and a double outlet right 
ventricle patient received inappropriate shocks due to sinus 
tachycardia and atrial tachycardia respectively. A beta blocker 
was effective in preventing further inappropriate ICD shocks in 
these two patients. 
Some complications occurred in 4 patients (27%) among our 
study population. There were no procedure related complications. 
However two patients required revision of ICD lead for the 
reconnection or repositioning of leads. A patient with CPVT 
suffered from ICD storm because of persistent polymorphic 
VT. For the recurrent nonsustained VT in this patient, the VT 
detection time was lengthened and the thoracoscopic left sym-
pathetic denervation surgery was added to minimize the ICD 
shock burden. 
Despite ICD implantation, concomitant medication was needed. 
Beta blockers such as atenolol, carvedilol, and propranolol were 
Figure 1. Chest X-ray demonstrates the ICD lead and device positions. 
(A) Transvenous positioning of a dual-coil ICD lead in an adolescent, 
(B) Epicardial positioning of ICD lead within pericardial sinus in 6 year old girl 
 
A  B 
Fig. 1. Chest X-ray scan demonstrating the implantable cardioverter defibrillator (ICD) lead and device 
positions: (A) transvenous positioning of a dual-coil ICD lead in an adolescent; (B) epicardial positioning of 
the ICD lead within the pericardial sinus of a 6-year-old girl.http://dx.doi.org/10.3345/kjp.2013.56.3.125
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used in 13 patients and sotalol in 2 patients. A patient with J wave 
syndrome received no medication. Among our patients, one 
died because of intractable heart failure. He was the youngest 
ICD case and genetically diagnosed as LQTS type 3 with dilated 
cardiomyopathy
9). There was no arrhythmia related sudden 
death during a follow-up period of 28.9 months (range, 4 to 59 
months).
Discussion
This study describes the early experience of pediatric ICD in 
Korea. Since 1996, the first case report of adult ICD implantation 
in Korea
10), ICD has been applied increasingly in high risk adult 
population to prevent sudden cardiac death. However the experi-
ence of ICD therapy in children and congenital heart disease 
patients is limited and there is only one pediatric case report
9), 
which case has been enrolled in this study. We have applied ICD 
for primary prevention in 2 patients and secondary pre  vention in 
13 patients. And the short term follow-up result was acceptable. 
Among 15 applied patients, 5 patients received the appropriate 
ICD shock therapy for 28.9±20.4 months (range, 4 to 59 months) 
of follow-up. In two young children (2 and 6 years old), ICD coils 
were implanted in the pericardial space. 
In approximately two thirds of sudden death in children and 
young adult, the underlying cardiac disease can be identified
1). 
The frequently identified cardiac causes are hypertrophic car-
diomyopathy, myocarditis, coronary artery abnormality, conduc-
tion system anomalies, and congenital heart disease
2,3). In an 
international multi-institutional study on LQTS, the overall 
incidence of sudden death was 8% and for hypertrophic cardio-
myopathy, the risk of sudden cardiac death was about 4%
11,12). 
 In contrast to ICD indications in adult ICD populations, 
children and young adults with ICD can be classified among 
three main categories of heart disease: ionic channelopathy, 
cardiomyopathy, and congenital heart disease. During the past 
15 years, the frequency of ICD implantation has been changed. 
In one of the earliest studies in 1993, a majority of the 125 
pediatric patients had cardiomyopathy (54%), followed by ionic 
channelopathy (26%), and congenital heart disease (18%)
13). 
The recent publications show there is a tendency of increased 
implantations in those with ionic channelopathy and congenital 
heart disease
5,14). The underlying disorders of this study were similar 
to those of western countries. 
In the past, ICD implantation in children and young adults 
has been reserved for secondary prevention. However, more 
recently the primary prevention has increased from 15% to 
almost 50%
5,13-16). This may reflect the impact of genetic testing on 
the decision making regarding device implantation, improved 
device technology, and the increased recognition of the risk 
of sudden death. The proportion of primary prevention in this 
study was lower than those of western countries. The reasons of 
this difference may be the difference of genetic background, late 
introduction of surgical correction of congenital heart disease, 
and the medico-social tendency of delaying ICD therapy in children 
in our country. As an ICD lead system, transvenous insertion is 
suitable for older children and adults. However, this system is not 
suitable in younger children and infants due to their small size and 
increased potential in venous obstruction. Furthermore, in children 
with congenital heart disease such as single-ventricle defects 
palliated with Fontan connections, cardiac and venous anatomy 
may prohibit a transvenous approach. Thus, an epicardial patch 
and subcuta  neous ICD system are the two common alternatives 
used in children when a transvenous approach is undesirable 
or not feasible
13-16). Epicardial patch ICD systems require a full 
sternotomy or thoracotomy and can lead to constrictive peri-
carditis. In addition, crinkling and failure of the epicardial 
patch can result in an increase in the DFT that requires lead 
revision in up to 25% of patients. A subcutaneous placement 
of an ICD lead or array in the chest wall avoids extensive ope-
rative exposure but may require at least a partial sternotomy 
for epicardial sense-pace electrode placement. And in compa-
rison to the transvenous approach, the epicardial patch or 
subcutaneous lead system has shown a problem of increase in 
the DFT
16-19). In 2 young children of 2 and 6 years old in this 
study, the ICD shock coils were implanted at the transverse sinus 
pericardially after median sternotomy. For epicardial approach, 
we used ICD shock coil which had been originally developed for 
transvenous application. Although the follow-up duration was 
short, the DFT was acceptable and there were several appropriate 
shock therapies in these 2 children. Five patients received the 
appropriate ICD shock therapies and two patients received 
inappropriate shocks due to supraventricular tachycardia. All 
appropriate therapies were observed in the patients for secondary 
prevention. Inappropriate therapy is usually triggered by sinus 
tachycardia, supraventricular tachycardia, T wave over-sensing 
and lead complications
20,21). An inappropriate ICD discharge results 
in significant morbidity, occurring in 13% to 40%, of young ICD 
patients within 4 years of implantation. This frequent occurrence 
might be attributed to higher heart rates, earlier lead failures 
related to increased activity, somatic growth, lead stress, and a 
longer life span with the ICD
22). 
The limitations of this study include its retrospective nature, 
the relatively short-term data collection, and the small sample 
size. However, since this is the first analysis of the current 
pediatric ICD experience in Korea, our results may be noteworthy.
In summary, ICD was a safe and reliable therapy for resusci  tated 
sudden death and syncope due to VT to prevent sudden death. 
The intrapericardial ICD lead positioning can be considered 
in small children who need epicardial ICD implan  tation. Early 129 http://dx.doi.org/10.3345/kjp.2013.56.3.125
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diagnosis and timely ICD implantation are recom  mended to 
prevent sudden death in high risk children and congenital heart 
disease patients.
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